Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Feb;125(2):295-302; quiz 303-4.
doi: 10.1016/j.jaci.2009.12.014.

The role of pharmacogenomics in improving the management of asthma

Shamsah Kazani  1 , Michael E Wechsler, Elliot Israel
Affiliations
Review

The role of pharmacogenomics in improving the management of asthma

Shamsah Kazani et al. J Allergy Clin Immunol. 2010 Feb.

Abstract

There is a large amount of interindividual variability in both therapeutic and adverse responses to asthma therapies. Genetic variability can account for 50% to 60% of this variability. Pharmacogenomics holds out the promise of allowing clinicians to prospectively choose therapies that have the greatest likelihood to be effective for individual patients and to avoid those that might have a high likelihood of producing adverse effects. In this article we review the principles of pharmacogenomic investigation. We explore the data developed from the early pharmacogenomic studies with the most common asthma therapies. Furthermore, we explore the potential use of pharmacogenomics, as well as caveats in interpreting such information.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Change in AM and PM PEF with regular use of albuterol from placebo (X axis) in B16 Arg/Arg vs. B16 Gly/Gly patients. Regular use of albuterol resulted in a decline in AM PEF in Arg/Arg patients while it produced an improvement in AM PEF in Gly/Gly individuals. Similar deteriorations in FEV1, symptoms, and reliever medication use were seen in Arg/Arg patients, while Gly/Gly patients improved (data not shown). Reference (18)
Figure 2
Figure 2
Improvement in FEV1 in association with different haplotypes of CRHR1. (49)
See this image and copyright information in PMC

References

    1. Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002 Mar;109(3):410–8. - PubMed
    1. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med. 2001 Sep 27;345(13):941–7. - PubMed
    1. Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005 Feb;115(2):233–42. - PubMed
    1. Palmer LJ, Silverman ES, Weiss ST, Drazen JM. Pharmacogenetics of asthma. Am J Respir Crit Care Med. 2002 Apr 1;165(7):861–6. - PubMed
    1. Van Eerdewegh P, Little RD, Dupuis J, Del Mastro RG, Falls K, Simon J, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature. 2002 Jul 25;418(6896):426–30. - PubMed

Publication types

Substances